Skip to main content

Table 2 # of subjects in each population positive for both anti-HERV K10 Gag & Pol antibodies

From: Increased seroreactivity to HERV-K10 peptides in patients with HTLV myelopathy

Population

N

# positive (%)

VBD*

100

0(0)

LGLL*

53

0(0)

HTLVt*

74

18(24)

HTLVm*+

16

14(88)

HTLVn*+

58

4(7)

MS*+

83

4(5)

  1. *p = 1.000, < 0.001, < 0.001, 0.017 and 0.041 for VBD vs LGLL, HTLVt, HTLVm; HTLVn; and MS, respectively.
  2. +p = < 0.001 for HTLVm vs HTLVn or vs MS.
Back to article page

Virology Journal

ISSN: 1743-422X